The DOI matches its Crossref record; 89 of the 91 references it cites were found in a registry or an index; 51 of the 105 sources its claims cite were checked for support.
Diagnostic Significance of Tryptase for Suspected Mast Cell Disorders
Open accessAbstract
Tryptase has proven to be a very useful and specific marker to demonstrate mast cell activation and degranulation when an acute (i.e., within 4 h after the event) and baseline value (i.e., at least 24 h after the event) are compared and meet the consensus formula (i.e., an increase of 20% + 2). The upper limit of normal determined by the manufacturer is 11.4 ng/mL; however, this boundary has been the subject of debate. According to ECNM and AIM experts, the normal range of baseline tryptase should be 1 to 15 ng/mL. A genetic trait, hereditary alpha tryptasemia, characterized by an increased alpha coding TPSAB1 copy number is associated with a baseline value above 8 ng/mL. Elevated tryptase can also be found in chronic kidney disease, obesity, and hematological neoplasms. A tryptase > 20 ng/mL serves as a minor criterion to diagnose systemic mastocytosis and an increase in tryptase > 20% + 2 during an acute event is a required criterion in the diagnosis of mast cell activation syndrome. The goal of this review is to demonstrate the (in)significance of tryptase using some clinical vignettes and to provide a practical guide on how to manage and interpret an elevated tryptase level.
Overview
CoChat Summary
TL;DR
This narrative review explains how serum tryptase should be interpreted for suspected mast cell disorders, emphasizing paired acute and baseline sampling and the 20% + 2 consensus formula. It uses seven clinical vignettes to show that elevated baseline tryptase is often due to hereditary alpha-tryptasemia or renal failure, while tryptase >20 ng/mL or a documented acute rise supports systemic mastocytosis or MCAS.
Key findings
- For suspected mast cell activation, acute tryptase should ideally be measured 30–120 min after symptom onset (up to 4 h), paired with baseline tryptase at least 24 h later; the consensus formula is aST ≥ [(1.2 × bST) + 2], i.e., an increase of 20% + 2 ng/mL.
- Baseline tryptase >20 ng/mL is a minor criterion for systemic mastocytosis, and documented mast cell activation by paired tryptase is a required criterion in mast cell activation syndrome; the manufacturer’s upper limit of normal is 11.4 ng/mL, but ECNM/AIM experts state the normal baseline range should be 1–15 ng/mL.
- Elevated baseline tryptase is most commonly caused by hereditary alpha-tryptasemia (91%), followed by chronic renal failure (7%) and hematologic malignancies/mastocytosis (1%); hereditary alpha-tryptasemia involves increased alpha-coding TPSAB1 copy number, is associated with baseline tryptase >8 ng/mL, and is found in up to 6% of the general population.
- In the vignettes, tryptase supported diagnoses such as indolent systemic mastocytosis (aST >200 ng/mL, bST 20 ng/mL), monoclonal MCAS (aST 909 ng/mL, bST 8.3 ng/mL), and hereditary alpha-tryptasemia (bST 19.1 ng/mL with alpha copy number 3 and beta copy number 2).
Methods
- Narrative review with no primary data collection; it synthesizes literature on tryptase biology, diagnostic criteria, and management of suspected mast cell disorders.
- Uses seven clinical vignettes (sections 2.1–2.7) of patients with suspected anaphylaxis or mast cell disorders to illustrate interpretation of acute and baseline tryptase.
- Main analysis is qualitative synthesis; no systematic search, meta-analysis, or formal diagnostic accuracy calculation is reported.
Limitations
- Stated: the clinical relevance of hereditary alpha-tryptasemia is still under debate because not everyone with the trait experiences mediator-related symptoms or anaphylaxis; the link between hereditary alpha-tryptasemia and systemic mastocytosis remains to be elucidated.
- Stated: the consensus formula may miss mast cell activation in some patients, especially food-induced anaphylaxis, where only a 30% tryptase increase may suffice; an aST/bST ratio above 1.685 requires further validation, and more research is needed on α/β-tryptase heterotetramers.
- Evident from the design: this is a narrative review with selected clinical vignettes, not a systematic review or prospective validation study, so the cases are illustrative rather than generalizable.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
38 Valid · 1 Not valid · 22 Not checked · 29 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Tryptase has proven to be a very useful and specific marker to demonstrate mast cell activation and degranulation when an acute (i.e., within 4 h after the event) and baseline value (i.e., at least 24 h after the event) are compared and meet the consensus formula (i.e., an increase of 20% + 2).”
§ Diagnostic Significance of Tryptase for Suspected Mast Cell Disorders > Abstract
What the sources say
- Partly supportedcites [10] Valent, 2019, Why the 20% + 2 Tryptase Formula Is a Diagnostic Gold Standard for Severe Systemic Mast Cell Activation and Mast Cell Activation Syndrome, Int. Arch. Allergy Immunol. sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) describes tryptase as a specific marker of severe systemic mast-cell activation, gives a 2–4-hour diagnostic window, and specifies an event-related rise of at least 20% over baseline plus 2 ng/mL. It says tryptase may take up to 24 hours to return to baseline, but does not explicitly prescribe collecting the baseline sample at least 24 hours after the event. The Summary and Future Perspectives also cautions that the formula usually does not capture mild or local activation, a limitation absent from the claim. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites [11] Ebo, 2021, Mast Cell Activation During Suspected Perioperative Hypersensitivity: A Need for Paired Samples Analysis, J. Allergy Clin. Immunol. Pract. source
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A tryptase > 20 ng/mL serves as a minor criterion to diagnose systemic mastocytosis and an increase in tryptase > 20% + 2 during an acute event is a required criterion in the diagnosis of mast cell activation syndrome.”
- Also stated in: § 1. Introduction · boosted
“Documented MCA based on paired tryptase samples is also a validated and required criterion in mast cell activation syndrome (MCAS).”
§ Diagnostic Significance of Tryptase for Suspected Mast Cell Disorders > Abstract
What the sources say
- Supportedcites [10] Valent, 2019, Why the 20% + 2 Tryptase Formula Is a Diagnostic Gold Standard for Severe Systemic Mast Cell Activation and Mast Cell Activation Syndrome, Int. Arch. Allergy Immunol. source
The Introduction (page unavailable) lists an event-related, transient serum tryptase rise of at least 20% above the individual’s baseline plus 2 ng/mL as one of the criteria for diagnosing MCAS. It specifies measurement within 2–4 hours after the reaction. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [11] Ebo, 2021, Mast Cell Activation During Suspected Perioperative Hypersensitivity: A Need for Paired Samples Analysis, J. Allergy Clin. Immunol. Pract. source
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § 1. Introduction · boosted
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“However, it seems to be a disease-modifying trait in anaphylaxis and PMCD [19,20,21].”
§ Diagnostic Significance of Tryptase for Suspected Mast Cell Disorders > 1. Introduction
What the sources say
- Not checked — no full text of the sourcecites [19] Beyens, 2022, Mastocytosis and related entities: A practical roadmap, Acta Clin. Belg. source
- Supportedcites [20] Rijavec, 2023, Clonal mast cell disorders and hereditary α-tryptasemia as risk factors for anaphylaxis, Clin. Exp. Allergy source
The Abstract calls HαT a genetic modifier of anaphylaxis. Section 3.3 (page not provided) reports that HαT-associated clonal mast cell disorders appear to have a distinct course and that patients with both HαT and systemic mastocytosis have more severe anaphylaxis. This supports the citing sentence’s hedged description of HαT as a disease-modifying trait. (LLM, conf=0.89)
- Not checked — no full text of the sourcecites [21] Carter, 2023, Extrinsic and Intrinsic Modulators of Anaphylaxis, J. Allergy Clin. Immunol. Pract. source
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“A tryptase > 20 ng/mL serves as a minor criterion to diagnose systemic mastocytosis and an increase in tryptase > 20% + 2 during an acute event is a required criterion in the diagnosis of mast cell activation syndrome.”
- Also stated in: § 1. Introduction · plain
“If bST is more than 20 ng/mL, a minor criterion for the diagnosis of systemic mastocytosis (SM) is met [12,13,14].”
§ Diagnostic Significance of Tryptase for Suspected Mast Cell Disorders > Abstract
What the sources say
- Could not verifycites [12] Valent, 2022, Global Classification of Mast Cell Activation Disorders: An ICD-10-CM-Adjusted Proposal of the ECNM-AIM Consortium, J. Allergy Clin. Immunol. Pract. sourceExperimental — accuracy not yet measured
The paper’s diagnostic-criteria section and Table I discuss a tryptase rise of 20% plus 2 ng/mL for mast cell activation syndrome, which is a different criterion. Searches for the 20 ng/mL threshold and minor criteria for systemic mastocytosis found no passage in our copy stating the attributed claim. (LLM, conf=0.72)
- Could not verifycites [13] Valent, 2022, Mast Cell Activation Syndromes: Collegium Internationale Allergologicum Update 2022, Int. Arch. Allergy Immunol. sourceExperimental — accuracy not yet measured
The Clinical Manifestations and Laboratory Correlates of MCA section says persistently elevated tryptase may point to occult mastocytosis. Searches for the 20 ng/mL threshold and minor diagnostic criteria found no passage in our copy stating that tryptase >20 ng/mL is a minor criterion for systemic mastocytosis. (LLM, conf=0.72)
- Supportedcites [14] Pardanani, 2023, Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management, Am. J. Hematol. source
Table 4 (section 2.1, Bone marrow histology) lists baseline serum tryptase >20 ng/mL as a minor criterion for systemic mastocytosis. It specifies that elevated tryptase does not count when there is an unrelated myeloid neoplasm and should be adjusted in known hereditary alpha-tryptasemia. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § 1. Introduction · plain
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Hereditary alpha-tryptasemia (HαT) is an autosomal dominant genetic trait of an increased copy number of the alpha-coding (of ≥2) TPSAB1-gene [15,16], which may account for elevated serum tryptase in the absence of clonal mast cell disorders.”
§ Diagnostic Significance of Tryptase for Suspected Mast Cell Disorders > 1. Introduction
What the sources say
- Supportedcites [15] Lyons, 2018, Hereditary Alpha Tryptasemia: Genotyping and Associated Clinical Features, Immunol. Allergy Clin. N. Am. source
The Introduction says inherited hereditary alpha tryptasemia is frequently a cause of elevated basal serum tryptase and distinguishes it from elevations due to clonal expansion of mast cells. The Associated clinical features section also discusses elevated tryptase in the absence of clonal mast cell disease. (LLM, conf=0.93)
- Not checked — no full text of the sourcecites [16] Lyons, 2016, Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number, Nat. Genet. source
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
40 more claims · 11 with their cited sources checked
Create a free account to see all 90 claims and to verify the 1 reference still open.
- Probably not a substantial claim. 22
- It may state two separate claims as one. 27
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“growing knowledge of hereditary alpha-tryptasemia (HαT), a germline condition causing increase in BST with not fully elucidated clinical consequences (4–6).”
From Defining “Normal” basal serum tryptase levels: a context-dependent approach to improve diagnostics in systemic mastocytosis (2025) · cites this paper as [6]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Diagnostic Significance of Tryptase for Suspected Mast Cell Disorders > 1. Introduction
“If bST is more than 20 ng/mL, a minor criterion for the diagnosis of systemic mastocytosis (SM) is met”
§ Diagnostic Significance of Tryptase for Suspected Mast Cell Disorders > 3. Discussion
“A bST ≥ 20 ng/mL is a minor criterion for the diagnosis of SM.”
Citations
Cites
Fatal and Near-Fatal Anaphylactic Reactions to Food in Children and Adolescents
Sampson, H. A., Mendelson, L., & Rosen, J. P. (1992) · New England Journal of Medicine · doi:10.1056/nejm199208063270603 · Cited by 1,609 · cited 1×
“This is especially true for patients with food-induced anaphylaxis [31,32], in which only a 30% increase in tryptase seems to suffice [33].”
BackgroundValent, P., Akin, C., Arock, M., Brockow, K., Butterfield, J. H., Carter, M. C., Castells, M., Escribano, L., Hartmann, K., Lieberman, P., et al. (2012) · International Archives of Allergy and Immunology · doi:10.1159/000328760 · Cited by 654
Diagnostic Value of Tryptase in Anaphylaxis and Mastocytosis
Schwartz, L. B. (2006) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2006.05.010 · Cited by 477 · cited 1×
“In acute settings, such as suspected anaphylaxis or MC mediator-related symptoms, an aST should ideally be measured from 30 up to 120 min after the start of symptoms since this will correspond with the peak value [24].”
BackgroundTryptase from human pulmonary mast cells. Purification and characterization
Schwartz, L. B., Lewis, R. A., & Austen, K. F. (1981) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)68496-6 · Cited by 419
Lyons, J. J., Yu, X., Hughes, J. D., Le, Q. T., Jamil, A., Bai, Y., Ho, N., Zhao, M., Liu, Y., O'Connell, M. P., et al. (2016) · Nature Genetics · doi:10.1038/ng.3696 · Cited by 394
Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal
Valent, P., Akin, C., Hartmann, K., Alvarez-Twose, I., Brockow, K., Hermine, O., Niedoszytko, M., Schwaab, J., Lyons, J. J., Carter, M. C., et al. (2021) · HemaSphere · doi:10.1097/hs9.0000000000000646 · Cited by 317
Costa, J. J., Demetri, G. D., Harrist, T. J., Dvorak, A. M., Hayes, D. F., Merica, E. A., Menchaca, D. M., Gringeri, A. J., Schwartz, L. B., & Galli, S. J. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.183.6.2681 · Cited by 268 · cited 1×
“An increase in SCF can induce MC hyperplasia and thus give rise to elevated bST [75].”
BackgroundDevelopment of a new, more sensitive immunoassay for human tryptase: use in systemic anaphylaxis
Schwartz, L. B., Bradford, T. R., Rouse, C., Irani, A.-M., Rasp, G., Van Der Zwan, J. K., & Van Der Linden, P.-W. G. (1994) · Journal of Clinical Immunology · doi:10.1007/bf01533368 · Cited by 263 · cited 1×
“The tryptase assay commercially available from Thermo Fisher ® (Waltham, MA, USA) ImmunoCAP measures all of these isoforms in monomeric and tetrameric form (i.e., total serum tryptase) [9].”
MethodLyons, J. J., Chovanec, J., O’Connell, M. P., Liu, Y., Šelb, J., Zanotti, R., Bai, Y., Kim, J., Le, Q. T., DiMaggio, T., et al. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.06.035 · Cited by 230 · cited 1×
“There is a consensus that H α T is a risk modifier of severe anaphylaxis [21,48–53].”
BackgroundSperr, W. R., Jordan, J.-H., Fiegl, M., Escribano, L., Bellas, C., Dirnhofer, S., Semper, H., Simonitsch-Klupp, I., Horny, H.-P., & Valent, P. (2002) · International Archives of Allergy and Immunology · doi:10.1159/000059404 · Cited by 207
Cited by
Diagnostic Utility of Biomarkers in Anaphylaxis: A Systematic Review and Meta-Analysis
Khalaf, R., Prosty, C. J., Davalan, W., Abrams, E. M., Kaouache, M., & Ben‐Shoshan, M. (2025) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2025.04.008 · Cited by 24
Role of Mast Cells and Their Mediators in Chronic Kidney Diseases
Tziastoudi, M., Cholevas, C., Eleftheriadis, T., Stefanidis, I., & Theoharides, T. C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26209981 · Cited by 8
“Its clinical utility is particularly evident when acute (within 4 h of an event) and baseline (at least 24 h after an event) serum levels are compared, following the consensus formula of a 20% + 2 ng/mL increase [98,99].”
Ma, Q., Hai, Y., Duan, Y., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1550694 · Cited by 5
Wang, B., Bai, H., Yuan, P., et al. (2025) · Thrombosis Research · doi:10.1016/j.thromres.2025.109351 · Cited by 4
Crupi, F., Caroprese, J., & Mannelli, F. (2025) · Frontiers in Allergy · doi:10.3389/falgy.2025.1592001 · Cited by 2
Metadata
- Authors
- Beyens, M., Toscano, A., Ebo, D., Gülen, T., & Sabato, V.
- Affiliations
- University of Antwerp (BE)
- Karolinska University Hospital (SE)
- Corresponding author
- Ebo, Didier
- Venue
- Diagnostics
- Publisher
- MDPI AG
- Published
- 2023-12-14
- Volume
- 13
- Issue
- 24
- Pages
- 3662
- ISSN
- 2075-4418 (ISSN-L)
- PMC
- PMC10742504
- OpenAlex
- W4389737509
- Cited by
- 22
- References
- 91
- Citations by year
- 2026: 11 · 2025: 8 · 2024: 3
- FWCI
- 0.61
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Diagnostics (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Research Foundation Flanders/Fonds Wetenschappelijk Onderzoek (1800614N, 1804518N)
- Konsul T.H.C. Bergh Foundation, Sweden (1800614N, 1804518N)
- Swedish Society of Medicine, Sweden (1800614N, 1804518N)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Mast cells and histamine
- Health Sciences › Medicine › Rheumatology › Eosinophilic Disorders and Syndromes
- Health Sciences › Medicine › Immunology and Allergy › Food Allergy and Anaphylaxis Research
- Keywords
- tryptase, mast cell activation, mast cell degranulation, mast cell disease, systemic mastocytosis, mast cell activation syndrome, hereditary alpha-tryptasemia, TPSAB1, upper limit of normal, chronic kidney disease, obesity, hematologic malignancies, diagnostic criteria
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Diagnostic Significance of Tryptase for Suspected Mast Cell Disorders. https://app.cochat.ai/papers/10.3390/diagnostics13243662
- The paper
- Beyens, M., Toscano, A., Ebo, D., Gülen, T., & Sabato, V. (2023). Diagnostic Significance of Tryptase for Suspected Mast Cell Disorders. Diagnostics. https://doi.org/10.3390/diagnostics13243662
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.